Introduction {#S0001}
============

Lung cancer is the most common cause of death in men in both developed and developing countries, and it has overtaken breast cancer as the main cause of cancer-related deaths among women in developing countries.[@CIT0001],[@CIT0002] The etiology of lung cancer is very complex. Most lung cancer is first detected when the volume of the mass reaches very large. Due to extensive local spread and distant metastasis, about 60% of lung cancer patients are incurable.[@CIT0003] Therefore, there is an urgent clinical need to find novel biomarkers as new targets for lung cancer therapy.

Keratins are intermediate fibers in epithelial cells, about 10 nm long, which are a component of the cytoskeleton and play a major role in cell protection and structural support.[@CIT0004],[@CIT0005] In humans, there are 54 functional keratins. Keratin 17 (KRT17, CK17) belong to type I keratin with a molecular weight of 48 KDa.[@CIT0006] Through extensive tissue screening, it was found that KRT17 was poorly expressed in mature epithelial tissues, selectively expressed in hyperplasia active cells such as stem cells or reserve cells in the epithelium, and also expressed in glandular myoepithelium. Surprisingly, KRT17 was regenerated and highly expressed in cancer tissues.[@CIT0007] KRT17 has been used as a diagnostic marker in various tumors, such as breast cancer,[@CIT0008],[@CIT0009] skin squamous cell carcinoma,[@CIT0010] and cervical cancer.[@CIT0011]

It was found that some keratins have regulatory functions, including cell movement, cell size, proliferation, apoptosis, and cell signal transduction.[@CIT0012]--[@CIT0015] In the early stage of human skin injury, expression levels of KRT17, KRT6, and KRT16 increased under the induction of inflammatory factors, and the time of wound healing was significantly shortened.[@CIT0016] In a mouse model of skin basaloid tumors with Gli2 gene transfection, KRT17 gene knockout significantly inhibited tumor development and growth.[@CIT0017] KRT17 was also found to be overexpressed in gastric cancer,[@CIT0012] cervical malignancy,[@CIT0011] breast carcinoma,[@CIT0008] oral squamous cell carcinoma,[@CIT0018] and pancreatic cancer,[@CIT0019] and is associated with poor prognosis of cervical cancer, gastric cancer, and oral squamous cell carcinoma.[@CIT0011],[@CIT0012],[@CIT0018] However, the function of KRT17 in the pathogenesis and progression of lung cancers remains unclear.

In this study, we found that KRT17 was overexpressed in non-small cell lung cancer (NSCLC) tissues and associated with poor prognosis. KRT17 promoted the proliferation and invasiveness of NSCLC by activating the Wnt signaling pathway and epithelial mesenchymal transition (EMT) process. Our findings suggested that KRT17 could be a valuable indicator of NSCLC progression and poor survival.

Materials and methods {#S0002}
=====================

Tissue specimens {#S0002-S2001}
----------------

Tissue specimens from 158 NSCLC patients who underwent surgical resection at the First Hospital of China Medical University between 2012 and 2015 were selected from the archival files of the Department of Pathology. Some lung cancer samples (32 cases) were accompanied by corresponding normal lung tissue samples. The age of patients ranged from 22 to 76 years, with a mean age of 54 years. There were 118 male and 40 female patients. The histological diagnoses and differentiation grades of the samples were classified according to the World Health Organization classification system as squamous cell carcinoma (n=78) and adenocarcinoma (n=80). The cancers were classified as well-differentiated (25 cases), moderately differentiated (92 cases), and poorly differentiated (41 cases). According to the seventh edition of the International Union against Cancer TNM Staging System for Lung Cancer,[@CIT0020] patients were categorized as stage I (n=44), II (n=61), III (n=51), and IV (n=2). Lymph node metastases were found in 85 cases. All patients had provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki, and under the regulations of the Institutional Review Board of China Medical University.

Immunohistochemistry {#S0002-S2002}
--------------------

An immunohistochemical assay was performed as previously described.[@CIT0021] KRT17 rabbit polyclonal antibody (1:1000; Proteintech, Wuhan, China) was used. The tissue sections were reviewed by two experienced evaluators without prior knowledge of the patient data. Five views were examined per slide, and 100 cells were observed per view at 400× magnification. Immunohistochemical results were scored considering both the proportion of positive cells and intensity of cell staining. The intensity of immunostaining was defined as follows: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The frequency of positive cells was scored as follows: 0 (\<5%), 1 (5--25%), 2 (26--50%), 3 (51--75%), and 4 (\>75%). The value obtained by multiplying the two scores was the final score of each case. Cases with a score less than 6 were classified as low expression of KRT17, while a score greater than or equal to 6 was classified as high expression of KRT17.

Cell culture and transfection {#S0002-S2003}
-----------------------------

Human lung cancer cell lines A549, H1299, and SK-MES-1 were purchased from American Type Culture Collection (Manassas, VA, USA) and validated by a DNA profiling assessment (short tandem repeat, STR). A549 and H1299 were cultured in RPMI 1640 (Gibco, Invitrogen, NY, USA), whereas SK-MES-1 was cultured in DMEM (Gibco, Invitrogen, NY, USA), supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen, NY, USA) at 37°C and 5% CO~2~. The cells were grown in sterile culture dishes and passaged every 1 or 3 d using 0.25% trypsin (Gibco, Invitrogen, NY, USA).

For transfection, the cells were seeded in a six-well plate 24 h or 48 h before the experiment. The KRT17 plasmid and empty control vectors were purchased from Genechem (Shanghai, China). Small interfering RNA (siRNA) against KRT17 (KRT17-siRNA) and control siRNA were synthesized by RiboBio (Guangzhou, China). The plasmids or siRNAs were transfected into cells using Lipofectamine^®^ 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

Western blot {#S0002-S2004}
------------

Total protein of cells was extracted with cell lysis buffer (Pierce, Rockford, IL, USA). Cell lysates were separated by 10% SDS-PAGE and then transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% non-fat milk for 2 h and incubated with corresponding antibodies overnight at 4°C. The primary antibodies used were as follows: KRT17 (1:1000, Proteintech, Wuhan, China), active-β-catenin (1:1000, Cell Signaling Technology, MA, USA), c-Myc (1:1000, Proteintech, Wuhan, China), cyclin D1 (1:100, Santa Cruz Biotechnology, CA, USA), MMP7 (1:100, Santa Cruz Biotechnology, CA, USA), GAPDH (1:2000, Santa Cruz Biotechnology, CA, USA), E-cadherin (1:1000, Cell Signaling Technology, MA, USA), Snail (1:500, Proteintech, Wuhan, China), MMP-9 (1:1000, Proteintech, Wuhan, China), and Vimentin (1:2000, Cell Signaling Technology, MA, USA). The membranes were incubated with diluted secondary antibody for 2 h. Protein bands were visualized using an ECL kit (Pierce) and detected using a bioimaging system (DNR, Jerusalem, Israel). GAPDH was used as a loading control. Image J software was used to quantify the results.

Cell proliferation assay {#S0002-S2005}
------------------------

Cells were seeded in a 96-well plate at 3000 cells/well. Cell proliferation was evaluated using the Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Tokyo, Japan) for 5 d. The CCK-8 reagent was added into each well at a 1:10 (v/v) dilution per 100 µL and incubated for 2 h at 37°C. The results were analyzed using an automated plate reader at 450 nm.

Colony formation assay {#S0002-S2006}
----------------------

Cells were plated on 6 cm cell culture dishes (800 cells per dish) and incubated for 10--14 d. The culture medium was refreshed every 4--5 d according to the color of the culture medium. The cells were fixed with methanol for 15 min and stained with crystal violet for 5 min. Colonies with more than 50 cells were counted.

Matrigel invasion assay {#S0002-S2007}
-----------------------

Transwell chambers (Costar, Cambridge, MA, USA) precoated with Matrigel (BD Biosciences, San Jose, CA, USA) were used to detect the invasiveness of the transfected cells. Briefly, 100 µL of Matrigel (1:7 dilution) was applied to each chamber, and the chambers were placed in a 37°C incubator for 2 h. Subsequently, 12×10^4^ cells, which were cultured in serum-free medium, were added into the upper chamber, and 0.6 mL medium supplemented with 20% FBS was added to the lower chamber as a chemoattractant. After 20--40 h of incubation, the filters were fixed with 4% paraformaldehyde for 20 min and stained with hematoxylin for 10 min. The non-invading cells on the upper surface were removed by scraping with a cotton swab. The number of cells that penetrated the membrane was counted under a microscope from five randomly selected fields.

Statistical analysis {#S0002-S2008}
--------------------

All statistical analyses were performed using SPSS 17.0 software (Chicago, IL, USA) and GraphPad Prism 5.0 software (La Jolla, CA, USA). The Chi--square test was used to examine possible correlations between KRT17 expression and clinicopathological factors. Other results were analyzed using two-tailed Student's *t*-test. *P*-values less than 0.05 were considered statistically significant.

Results {#S0003}
=======

Upregulated KRT17 expression in lung cancer tissues {#S0003-S2001}
---------------------------------------------------

We examined the expression of KRT17 in 158 lung cancers and 32 normal lung tissue samples. The expression of KRT17 was only observed in a few basal cells in bronchial epithelium in normal tissues, but negative in matured bronchial epithelia and alveolar epithelia ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}). High expression of KRT17 was found in 81 cases (51%) of NSCLC, including 56 cases (71.8%) of lung squamous cell carcinomas (LUSC) ([Figure 1C](#F0001){ref-type="fig"}) and 25 cases (31.2%) of lung adenocarcinomas (LUAD) ([Figure 1E](#F0001){ref-type="fig"}). There were 22 cases (28.2%) of LUSCs ([Figure 1D](#F0001){ref-type="fig"}) and 55 cases (68.8%) of LUADs ([Figure 1F](#F0001){ref-type="fig"}) with low expression of KRT17. The expression level of KRT17 was significantly higher in both LUAD and LUSC tissues than that in normal lung tissues (*P*\<0.001) ([Table 1](#T0001){ref-type="table"}). To confirm the expression level of KRT17 in lung cancer tissues, we retrieved and analyzed the mRNA expression levels of KRT17 using the online database UALCAN (<http://ualcan.path.uab.edu/analysis.html>).[@CIT0022] The expression level of KRT17 was significantly elevated in both LUADs (*P*\<0.001) and LUSCs (*P*\<0.001) compared to normal lung tissues ([Figure S1](#SD1){ref-type="supplementary-material"}).Table 1Correlations between KRT17 expression and clinicopathological factors in lung cancersnKRT17 low expressionKRT17 high expression*P-*valueTissuesNormal3232 (100.0%)0\<0.001**\*\***Lung cancer15877 (49.0%)81 (51.0%)Age\<608448 (57.1%)36 (42.9%)0.024**\***≥607429 (39.2%)45 (60.8%)GenderMale11846 (39.0%)72 (61.0%)\<0.001\*\*Female4031 (77.5%)9 (22.5%)Histological typeSquamous cell carcinoma7822 (28.2%)56 (71.8%)\<0.001\*\*Adenocarcinoma8055 (68.8%)25 (31.2%)DifferentiationWell2518 (72.0%)7 (28.0%)0.011\*Moderate-Poor13359 (44.4%)74 (55.6%)TNM stagesI4419 (43.2%)25 (56.8%)0.121II6136 (59.0%)25 (41.0%)III-IV5322 (41.5%)31 (58.5%)Lymphatic metastasisYes7342 (57.5%)31 (42.5%)0.04\*No8535 (41.2%)50 (58.8%)[^1][^2] Figure 1Immunohistochemical staining of KRT17 in non-small cell lung cancers and normal lung tissues. (**A** and **B**), KRT17 expression was negative in matured normal bronchial epithelial cells (**A**) and alveolar pneumocytes (**B**), but positive in partial basal cells under the normal bronchial epithelial cells (200×). (**C)** High expression of KRT17 in a representative lung squamous cell carcinoma case (200×). (**D**) Negative expression of KRT17 in a representative lung squamous cell carcinoma case (200×). (**E**) High expression of KRT17 in a representative lung adenocarcinoma case (200×). (**F**) Negative expression of KRT17 in a representative lung adenocarcinoma case (200×).

KRT17 expression correlates with clinicopathological factors and indicates poor prognosis in non-small cell lung cancer patients {#S0003-S2002}
--------------------------------------------------------------------------------------------------------------------------------

The high expression of KRT17 was associated with the histological type (*P*\<0.001), lymph node metastasis (*P*=0.040), differentiation (*P*=0.011), age (*P*=0.024), and gender (*P*\<0.001), but did not correlate with TNM stage (*P*=0.121), of NSCLC ([Table 1](#T0001){ref-type="table"}). In LUADs, high KRT17 expression was associated with poor differentiation (*P*=0.036), advanced TNM stage (*P*=0.005) and lymph node metastasis (*P*=0.011). However, KRT17 expression was not correlated with the age (*P*=0.100) and gender (*P*=0.183) of LUAD patients ([Table 2](#T0002){ref-type="table"}). In LUSCs, high expression of KRT17 was only associated with gender (*P*=0.002), but not correlated with age (*P*=0.990), differentiation (*P*=0.982), TNM stage (*P*=0.974), or lymphatic metastasis (*P*=0.431) ([Table 3](#T0003){ref-type="table"}).Table 2Correlations between KRT17 expression and clinicopathological factors in lung adenocarcinomasnKRT17 low expressionKRT17 high expression*P-*valueTissuesNormal3232 (100.0%)0**\<**0.001**\*\***Adenocarcinoma8055 (68.8%)25 (31.2%)Age\<605239 (75.0%)13 (25.0%)0.100≥602816 (57.1%)12 (42.9%)GenderMale4931 (63.3%)18 (36.7%)0.183Female3124 (77.4%)7 (22.6%)DifferentiationWell1816 (88.9%)2 (11.1%)0.036\*Moderate-Poor6239 (62.9%)23 (37.1%)TNM stagesI1210 (83.3%)2 (16.7%)0.005\*\*II3529 (82.9%)6 (17.1%)III--IV3316 (48.5%)17 (51.5%)Lymphatic metastasisYes3630 (83.3%)6 (16.7%)0.011\*No4425 (56.8%)19 (43.1%)[^3][^4] Table 3Correlations between KRT17 expression and clinicopathological factors in lung squamous cell carcinomasnKRT17 low expressionKRT17 high expression*P-*valueTissuesNormal3232 (100.0%)0\<0.001**\*\***Squamous cell cancer7822 (28.2%)56 (71.8%)Age\<60329 (28.1%)23 (71.9%)0.990≥604613 (28.3%)33 (71.7%)GenderMale6915 (21.7%)54 (78.3%)0.002\*\*Female97 (77.8%)2 (22.2%)DifferentiationWell72 (28.6%)5 (71.4%)0.982Moderate-Poor7120 (28.2%)51 (71.8%)TNM stagesI329 (28.1%)23 (71.9%)0.974II267 (26.9%)19 (73.1%)III--IV206 (30.0%)14 (70.0%)Lymphatic metastasisYes3712 (32.4%)25 (67.6%)0.431No4110 (24.4%)31 (75.6%)[^5][^6]

To further investigate the prognostic value of KRT17, we retrieved the Kaplan-Meier curves of KRT17 in lung cancers from two online databases, UALCAN and KM-plotter (<http://kmplot.com/analysis/>).[@CIT0023] In total lung cancers, the survival time was shorter in patients with high KRT17 expression than in patients with low KRT17 expression (*P*\<0.001, [Supplementary Figure 1](#F0001){ref-type="fig"}). High expression of KRT17 also indicated poor survival in LUADs (*P*=0.014, [Supplementary Figure 1](#F0001){ref-type="fig"}), which was consistent with total lung cancers. However, KRT17 expression was not correlated with LUSC prognosis (*P*=0.890, [Figure S1](#SD1){ref-type="supplementary-material"}).

KRT17 promotes proliferation, colony formation, and invasiveness of non-small lung cancer cells {#S0003-S2003}
-----------------------------------------------------------------------------------------------

We elevated KRT17 expression by gene transfection in A549 (A549-KRT17) and H1299 (H1299-KRT17) cells. Further, KRT17 expression was knocked down by siRNA interference in SK-MES-1 cells (SK-siKRT17). In A549-KRT17 and H1299-KRT17 cells, overexpression of KRT17 promoted proliferation (*P*\<0.05 and *P*\<0.05, respectively) ([Figure 2A](#F0002){ref-type="fig"}) colony formation (*P*=0.010 and *P*=0.032, respectively) ([Figure 2B](#F0002){ref-type="fig"}) and invasiveness (*P*=0.002 and *P*=0.001, respectively) ([Figure 2C](#F0002){ref-type="fig"}). In contrast, down-regulation of KRT17 inhibited proliferation (*P*\<0.05), colony formation (*P*=0.003), and invasiveness (*P*\<0.001) of SK-siKRT17 cells ([Figure 2A](#F0002){ref-type="fig"}--[C](#F0002){ref-type="fig"}).Figure 2Promotion of proliferation, colony formation, and invasiveness by KRT17 in non-small cell lung cancer cells. (**A**) Cell growth curves of A549 and H1299 cells transfected with KRT17 gene (A549-KRT17 and H1299-KRT17), SE-MES-1 cells interfered with siKRT17 (SE-MES-1-siKRT17), and their control cells (NC and siNC). (**B**) Representative images of the colony formation assay for A549-KRT17, H1299-KRT17, SE-MES-1-siKRT17, and their control cells. The number of colonies formed by each group is shown in the histogram. (**C**) Representative images of the Matrigel invasion assay for A549-KRT17, H1299-KRT17, SE-MES-1-siKRT17, and their control cells. The invasive cell number for each group is shown in the histogram. \**P*\<0.05; \*\**P*\<0.01.**Abbreviations:** NC, negative control cell; siNC, small interfering RNA negative control cell.

KRT17 enhances β-catenin activity and increases expression levels of Wnt target genes {#S0003-S2004}
-------------------------------------------------------------------------------------

We investigated the effects of KRT17 on β-catenin and LFF-1 expression, key proteins of the Wnt signaling pathway, and the target proteins of the Wnt pathway, such as cyclin D1, c-Myc, and MMP7. KRT17 was highly expressed in A549-KRT17 and H1299-KRT17 cells. During KRT17 overexpression, expression levels of active-β-catenin, cyclinD1, c-Myc, and MMP7 were upregulated in A549-KRT17 cells and H1299-KRT17 cells compared to their control cells (*P*\<0.05) ([Figure 3A](#F0003){ref-type="fig"}, [B](#F0003){ref-type="fig"}, [D](#F0003){ref-type="fig"} and [E](#F0003){ref-type="fig"}). In contrast, compared to SK-MES-1 control cells, KRT17 expression was down-regulated in SK-siKRT17 cells. The levels of active-β-catenin, cyclinD1, c-Myc, and MMP7 were also reduced in SK-siKRT17 cells compared to control cells (*P*\<0.05) ([Figure 3C](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}). However, the expression level of LEF-1 was not significantly changed in A549-KRT17, H1299-KRT17, and SK-siKRT17 cells compared to their respective control cells (*P\>*0.05).Figure 3Expression of Wnt signaling pathway- and EMT-related proteins in non-small cell lung cancer cells after KRT17 overexpression or knockdown. (**A, B**, and **C**) Western blot analysis for proteins relevant to the Wnt signaling pathway and EMT in A549-KRT17 (**A**), H1299-KRT17 (**B**), SE-MES-1-siKRT17 (**C**), and their control cells. GAPDH served as an internal control. (**D, E**, and **F**) Relative expression levels of proteins for each group are shown in the histogram. \**P*\<0.05; \*\**P*\<0.01.**Abbreviations:** EMT, epithelial mesenchymal transition; NC, negative control cell; siNC, small interfering RNA negative control cell; siKRT17, small interfering RNA against keratin 17.

KRT17 promotes EMT process of non-small cell lung cancer cells {#S0003-S2005}
--------------------------------------------------------------

We investigated the effect of KRT17 on expression of EMT-related proteins in lung cancer cells. As shown in [Figure 3A](#F0003){ref-type="fig"}, [B](#F0003){ref-type="fig"}, [D](#F0003){ref-type="fig"} and [E](#F0003){ref-type="fig"}, the expression levels of Vimentin, MMP9, and Snail were increased, yet E-cadherin expression was reduced, in A549-KRT17 and H1299-KRT17 cells compared to their control cells (*P*\<0.05). Further, with KRT17 knockdown, the opposite results were obtained in SK-siKRT17 cells (*P*\<0.05) ([Figure 3C](#F0003){ref-type="fig"} and [F](#F0003){ref-type="fig"}).

Discussion {#S0004}
==========

KRT17 promotes carcinogenesis of a variety of cancer types, including gastric cancer,[@CIT0012] cervical cancer,[@CIT0011] breast cancer[@CIT0009] and oral squamous cell carcinoma.[@CIT0024] However, few studies were conducted on KRT17 in lung cancers. Its role and underlying mechanism remain unclear. In this study, our immunohistochemical results and The Cancer Genome Atlas (TCGA) data both confirmed that KRT17 was highly expressed in NSCLC tissues. High expression of KRT17 was correlated with poor differentiation and lymphatic metastasis, and it indicated poor prognosis in NSCLC, especially in lung adenocarcinomas. All these results indicate that KRT17 can be a marker of lung cancer progression and a predictor of poor survival. The high expression and cancer-promotion role of KRT17 was also confirmed in other cancers. Luisa et al demonstrated that KRT17 expression was increased in atypical metaplasia, high-grade intraepithelial neoplasia, and squamous cell carcinoma of the cervix and was related to patient mortality.[@CIT0011] KRT17 was also found significantly increased in gastric cancer[@CIT0012] and oral squamous cell carcinoma,[@CIT0018] which was correlated with poor survival. In addition, the expression level of KRT17 was significantly higher in LUSCs than that in LUADs, suggesting KRT17 as a possible differential diagnostic marker of these two cancer types. As a member of keratins and displaying characteristic expression patterns in tumors, KRT17 has been reported as a diagnostic marker in pathological diagnosis of cancers, such as breast cancer,[@CIT0008],[@CIT0009] skin squamous cell carcinoma,[@CIT0010] and cervical cancer.[@CIT0011] Consistent with our opinion, Yuan et al considered that the immunohistochemical staining of cytokeratin (CK) 5/6, CK7, CK14, CK17, and CK18 could be useful for differentiated diagnosis of LUAD and LUSC.[@CIT0025]

Our in vitro studies showed that KRT17 overexpression promoted the proliferative and invasive abilities of lung cancer cells, which confirmed the cancer-promotion role of KRT17 and were consistent with previous reports in other cancers.[@CIT0014],[@CIT0026] It was reported that KRT17 facilitates cell proliferation in gastric cancer.[@CIT0014] Knock-out of the KRT17 gene significantly inhibited the migration and invasion process in areca nut-induced oral squamous cell carcinoma.[@CIT0026] The underlying mechanism of KRT17 promotion of cancer progression has been investigated in oral squamous cell carcinoma. Mikami et al found that phosphorylated KRT17 interacts with 14-3-3 sigma, which then activates the AKT/mTOR signaling pathway to promote cell proliferation in oral squamous cell carcinoma.[@CIT0027] It was also shown that KRT17 was a downstream signaling molecule of GLI1/2 in oral squamous carcinoma, which was overexpressed under the regulation of GLIs. KRT17 affects cell proliferation through an anti-apoptotic effect.[@CIT0018] However, the underlying mechanism of KRT17 in lung cancer has not been addressed previously.

Abnormal activation of the Wnt signaling pathway plays a key role in the promotion of various malignant tumors, including lung cancer.[@CIT0021],[@CIT0028],[@CIT0029] Wnt signaling pathway was first reported by Nusse and Varmus in 1982.[@CIT0030],[@CIT0031] Activation of the Wnt pathway leads to malignant transformation, and eventually tumor formation.[@CIT0032] To date, there have been no reports regarding KRT17 involvement in the Wnt signaling pathway. In this study, our results indicated that KRT17 upregulated activation of β-catenin, the core effector of the Wnt signaling pathway, and enhanced expression levels of Wnt target genes, such as cyclin D1, MMP7 and c-Myc. Moreover, overexpression of KRT17 markedly enhanced expression of MMP9, Snail, and Vimentin, and reduced expression of E-cadherin, which are EMT markers. Similarly, other keratins, such as KRT19, also can promote cell invasion and metastasis in human hepatocellular carcinoma.[@CIT0033] Taken together, KRT17 is not only an epithelial marker, but also a regulator of signaling pathways, Such as Wnt and AKT/mTOR signaling pathways. So, KRT17 can promote EMT process and the proliferative and invasive abilities of NSCLC cells via enhancing activity of the Wnt signaling pathway.

Conclusion {#S0005}
==========

We identified KRT17 as a commonly upregulated protein in NSCLC, and its expression corresponded to poor prognosis of NSCLC, especially adenocarcinomas. KRT17 promotes proliferation and invasion of NSCLC cells via activation of the Wnt signaling pathway and EMT. Therefore, KRT17 may be an indicator of poor survival and a potential therapeutic target of NSCLC.

Supplementary material {#S0011}
======================

Figure S1Expression levels of KRT17 in non-small cell lung cancers and normal lung tissues, and its correlation with prognosis. A and B, Box-plots of KRT17 expression levels in lung adenocarcinomas (LUAD) (**A**) and lung squamous cell carcinomas (LUSC) (**B**) compared to normal lung tissues, which were retrieved from the UALCAN database. (**C**) Kaplan--Meier curve of KRT17 expression in lung cancer tissues, as retrieved from the KM-plotter database. (**D** and **E**), Kaplan--Meier curves of KRT17 expression in LUAD (**D**) and LUSC (**E**), as retrieved from the UALCAN database.\*\*\**P* \<0.001
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